全文获取类型
收费全文 | 15933篇 |
免费 | 1274篇 |
国内免费 | 445篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 107篇 |
妇产科学 | 4173篇 |
基础医学 | 1966篇 |
口腔科学 | 7篇 |
临床医学 | 1066篇 |
内科学 | 488篇 |
皮肤病学 | 88篇 |
神经病学 | 82篇 |
特种医学 | 237篇 |
外国民族医学 | 16篇 |
外科学 | 601篇 |
综合类 | 2955篇 |
现状与发展 | 2篇 |
预防医学 | 973篇 |
眼科学 | 3篇 |
药学 | 936篇 |
8篇 | |
中国医学 | 707篇 |
肿瘤学 | 3235篇 |
出版年
2024年 | 17篇 |
2023年 | 205篇 |
2022年 | 354篇 |
2021年 | 731篇 |
2020年 | 572篇 |
2019年 | 489篇 |
2018年 | 530篇 |
2017年 | 684篇 |
2016年 | 708篇 |
2015年 | 639篇 |
2014年 | 1134篇 |
2013年 | 1223篇 |
2012年 | 913篇 |
2011年 | 1023篇 |
2010年 | 837篇 |
2009年 | 772篇 |
2008年 | 809篇 |
2007年 | 782篇 |
2006年 | 823篇 |
2005年 | 702篇 |
2004年 | 561篇 |
2003年 | 517篇 |
2002年 | 419篇 |
2001年 | 363篇 |
2000年 | 318篇 |
1999年 | 235篇 |
1998年 | 170篇 |
1997年 | 156篇 |
1996年 | 145篇 |
1995年 | 138篇 |
1994年 | 112篇 |
1993年 | 101篇 |
1992年 | 81篇 |
1991年 | 65篇 |
1990年 | 48篇 |
1989年 | 49篇 |
1988年 | 34篇 |
1987年 | 28篇 |
1986年 | 19篇 |
1985年 | 19篇 |
1984年 | 31篇 |
1983年 | 20篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 13篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 500 毫秒
1.
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素(luteinizing hormone,LH)水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。 相似文献
2.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
3.
目的比较多囊卵巢综合征(PCOS)妊娠患者与非PCOS孕妇的妊娠结局。方法选取200例PCOS妊娠患者作为研究组,并选取同期200例非PCOS孕妇作为对照组,比较两组孕妇的妊娠结局、新生儿情况及妊娠期并发症情况。结果研究组的先兆流产、早产、足月剖宫产发生率显著高于对照组(P <0.05);两组的先兆早产发生率比较无统计学差异(P>0.05)。两组的新生儿情况比较无统计学差异(P>0.05)。研究组的妊娠期高血压综合征、妊娠期糖尿病、羊水异常、胎儿窘迫发生率显著高于对照组(P <0.05)。结论与非PCOS孕妇相比,PCOS妊娠患者的早产风险增加,且妊娠期高血压综合征、妊娠期糖尿病、羊水异常、胎儿窘迫发生率显著升高。 相似文献
4.
5.
目的:探讨维生素D对多囊卵巢综合征(PCOS)患者胰岛素抵抗(IR)的影响及其机制研究.方法:选取自2013年2月~2014年2月在该院就诊的48例PCOS患者作为PCOS组,另选30例健康育龄期妇女作为对照组,测量研究者身高、体质量参数,计算体质指数(BMI),采用全自动生化分析仪葡萄糖氧化酶检测空腹血糖浓度(FBG)、化学发光法检测血清空腹胰岛素(FI)及胰岛素样生长因子-1(IGF-1)水平、ELISA方法测定血清25-(OH)D3浓度,计算稳态胰岛素评价指数(HOMA-IR)用于评价胰岛素抵抗性,量化胰岛素敏感指数(QUICKI)用于评价胰岛素敏感度,并分析FI、HOMA-IR、QUICKI及IGF-1与血清25-(OH)D3浓度的相关性.结果:PCOS组BMI及FBG与对照组相比,差异无统计学差异(P>0.05),而FI、HOMA-IR、QUICKI、25-(OH) D3及IGF-1与对照组比较,差异均有统计学差异(P<0.05);并且PCOS组FI和HOMA-IR与血清25-(OH)D3浓度呈显著负相关,差异有统计学意义(P<0.05),QUICKI和IGF-1水平与血清25-(OH)D3浓度呈显著正相关,差异有统计学意义(P<0.05).结论:PCOS患者IR可能与血清中维生素D缺乏有关,而IGF-1分泌减少又可能是导致PCOS患者维生素D缺乏的重要原因. 相似文献
6.
Elisa Malacarne Marta Devesa Francisca Martinez Ignacio Rodriguez Buenaventura Coroleu 《Journal of assisted reproduction and genetics》2020,37(12):3069
PurposeBreast cancer is the most common cancer diagnosed during childbearing age, and fertility preservation is becoming increasingly more essential. However, recent studies indicate a possible poorer response to controlled ovarian hyperstimulation (COH) in cancer patients than in non-cancer controls and a negative impact of BRCA mutations on female fertility. This study aims to evaluate ovarian response and the number of mature oocytes (MII) vitrified in women with breast cancer, with or without BRCA mutation, comparing them to the expected response according to an age-related nomogram.MethodsThis is a retrospective observational study involving sixty-one breast cancer patients who underwent COH for oocyte cryopreservation. The age-specific nomogram was built using 3871 patients who underwent COH due to oocyte donation, fertility preservation for non-medical reasons, or FIVET for male factor exclusively.ResultsThe mean number of oocytes retrieved was 13.03, whereas the mean number of MII oocytes was 10.00. After the application of the z-score, no statistically significant differences were found compared with the expected response in the general population, neither by dividing patients according to the presence or absence of BRCA mutation nor according to the phase in which they initiated stimulation.ConclusionThe results obtained do not support the notion of a negative impact of the BRCA mutation on the ovarian response of women with breast cancer. Women with breast cancer undergoing COH for fertility preservation can expect the ovarian response predicted for their age. 相似文献
7.
目的:探讨彩色多普勒超声诊断卵巢肿瘤蒂扭转的临床意义。方法方便选取2012―2015年该院收治的58例疑似卵巢肿瘤蒂扭转患者作为观察目标,入选病例均应用彩色多普勒超声进行检查,并将检查结果同术后病理检查结果进行比较。结果58例患者中,术后病理证实卵巢肿瘤蒂扭转者51例,彩色多普勒超声共确诊49例,检查准确率为96.1%;囊壁增厚、腹腔或盆腔积液、可见混合型团块是卵巢肿瘤蒂扭转的主要彩超表现。结论卵巢肿瘤蒂扭转应用彩色多普勒超声诊断,可显著提高诊断准确率,具有积极的临床使用和推广价值。 相似文献
8.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
9.
10.
M. Iachina P.M. Ljungdalh R.G. Sørensen L. Kaerlev J. Blaakær O. Trosko N. Qvist B.M. Nørgård 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):115-123